{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-041986","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2022-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.407593+00:00","generated_at":"2026-06-26T09:40:51.850594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eloxx Q4 net loss $12.1M; CF Foundation awards up to $15.9M; new Alport program","bullets":["Net loss $12.1M in Q4 2021 ($0.14/sh); cash $42.3M; expects funding into Q2 2023.","CF Foundation therapeutic award up to $15.9M for ELX-02 CF program; $7.0M upfront.","Phase 2 CF expansion (ELX-02+ivacaftor) topline results expected by end of H1 2022.","New Alport syndrome program for ELX-02; proof-of-concept trial in up to 8 patients expected H2 2022.","ZKN-013 FAP mouse model: 50% reduction in polyp burden, 40% in polyp count; 50% survival benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-041986","json":"https://secwatch.observer/filing/0001104659-22-041986.json","markdown":"https://secwatch.observer/filing/0001104659-22-041986.md","text":"https://secwatch.observer/filing/0001104659-22-041986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922041986/0001104659-22-041986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922041986/tm2211418d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:40:51.850594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}